{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:39:11Z","timestamp":1790699951103,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s00415-025-13202-0","type":"journal-article","created":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T05:12:55Z","timestamp":1750309975000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Influence of triptans use on anti-CGRP mAbs response: a prospective, cohort study"],"prefix":"10.1007","volume":"272","author":[{"given":"Catello","family":"Vollono","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6016-3141","authenticated-orcid":false,"given":"Marina","family":"Romozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Munaf\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Vigani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"De Cesaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Calabresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi Francesco","family":"Iannone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,19]]},"reference":[{"issue":"3","key":"13202_CR1","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/s1474-4422(21)00409-9","volume":"21","author":"L Al-Hassany","year":"2022","unstructured":"Al-Hassany L, Goadsby PJ, Danser AHJ, MaassenVanDenBrink A (2022) Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions. Lancet Neurol 21(3):284\u2013294. https:\/\/doi.org\/10.1016\/s1474-4422(21)00409-9","journal-title":"Lancet Neurol"},{"issue":"1","key":"13202_CR2","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s10194-021-01335-2","volume":"22","author":"F Vandervorst","year":"2021","unstructured":"Vandervorst F, Van Deun L, Van Dycke A, Paemeleire K, Reuter U, Schoenen J, Versijpt J (2021) CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs. J Headache Pain 22(1):128. https:\/\/doi.org\/10.1186\/s10194-021-01335-2","journal-title":"J Headache Pain"},{"issue":"1","key":"13202_CR3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, Amin FM, Ashina M, Bendtsen L, Deligianni CI, Gil-Gouveia R, Katsarava Z, MaassenVanDenBrink A, Martelletti P, Mitsikostas D-D, Ornello R, Reuter U, Sanchez-del-Rio M, Sinclair AJ, Terwindt G, Uluduz D, Versijpt J, Lampl C (2022) European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention\u20142022 update. J Headache Pain 23(1):67. https:\/\/doi.org\/10.1186\/s10194-022-01431-x","journal-title":"J Headache Pain"},{"key":"13202_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/head.14692","author":"AC Charles","year":"2024","unstructured":"Charles AC, Digre KB, Goadsby PJ, Robbins MS, Hershey A (2024) Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American Headache Society position statement update. Headache. https:\/\/doi.org\/10.1111\/head.14692","journal-title":"Headache"},{"issue":"1","key":"13202_CR5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s10194-023-01552-x","volume":"24","author":"B Raffaelli","year":"2023","unstructured":"Raffaelli B, Fitzek M, Overeem LH, Storch E, Terhart M, Reuter U (2023) Clinical evaluation of super-responders vs. non-responders to CGRP(-receptor) monoclonal antibodies: a real-world experience. J Headache Pain 24(1):16. https:\/\/doi.org\/10.1186\/s10194-023-01552-x","journal-title":"J Headache Pain"},{"issue":"7","key":"13202_CR6","doi-asserted-by":"publisher","first-page":"934","DOI":"10.3390\/ph16070934","volume":"16","author":"JB Hong","year":"2023","unstructured":"Hong JB, Lange KS, Overeem LH, Triller P, Raffaelli B, Reuter U (2023) A scoping review and meta-analysis of anti-CGRP monoclonal antibodies: predicting response. Pharmaceuticals 16(7):934","journal-title":"Pharmaceuticals"},{"issue":"12","key":"13202_CR7","doi-asserted-by":"publisher","first-page":"033310242412627","DOI":"10.1177\/03331024241262751","volume":"44","author":"M Romozzi","year":"2024","unstructured":"Romozzi M, Lokhandwala A, Vollono C, Vigani G, Burgalassi A, Garc\u00eda-Azor\u00edn D, Calabresi P, Chiarugi A, Geppetti P, Iannone LF (2024) An evolving machine-learning-based algorithm to early predict response to anti-CGRP monoclonal antibodies in patients with migraine. Cephalalgia 44(12):03331024241262751. https:\/\/doi.org\/10.1177\/03331024241262751","journal-title":"Cephalalgia"},{"issue":"1","key":"13202_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-020-01213-3","volume":"22","author":"I Frattale","year":"2021","unstructured":"Frattale I, Caponnetto V, Casalena A, Assetta M, Maddestra M, Marzoli F, Affaitati G, Giamberardino MA, Viola S, Gabriele A, Pistoia F, Cerone D, Marini C, Sacco S, Ornello R (2021) Association between response to triptans and response to erenumab: real-life data. J Headache Pain 22(1):1. https:\/\/doi.org\/10.1186\/s10194-020-01213-3","journal-title":"J Headache Pain"},{"issue":"4","key":"13202_CR9","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1111\/ene.15197","volume":"29","author":"F Vernieri","year":"2022","unstructured":"Vernieri F, Altamura C, Brunelli N, Costa CM, Aurilia C, Egeo G, Fofi L, Favoni V, Lovati C, Bertuzzo D, d\u2019Onofrio F, Doretti A, Di Fiore P, Finocchi C, Schiano Di Cola F, Ranieri A, Colombo B, Bono F, Albanese M, Cevoli S, Barbanti P (2022) Rapid response to galcanezumab and predictive factors in chronic migraine patients: a 3-month observational, longitudinal, cohort, multicenter, Italian real-life study. Eur J Neurol 29(4):1198\u20131208. https:\/\/doi.org\/10.1111\/ene.15197","journal-title":"Eur J Neurol"},{"issue":"3","key":"13202_CR10","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.pharmthera.2012.08.011","volume":"136","author":"L Edvinsson","year":"2012","unstructured":"Edvinsson L, Villal\u00f3n CM, MaassenVanDenBrink A (2012) Basic mechanisms of migraine and its acute treatment. Pharmacol Ther 136(3):319\u2013333. https:\/\/doi.org\/10.1016\/j.pharmthera.2012.08.011","journal-title":"Pharmacol Ther"},{"issue":"1","key":"13202_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The international classification of headache disorders, 3rd edition. Cephalalgia 38(1):1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202","journal-title":"Cephalalgia"},{"issue":"3","key":"13202_CR12","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/j.1468-2982.2005.01016.x","volume":"26","author":"P Sarchielli","year":"2006","unstructured":"Sarchielli P, Pini LA, Zanchin G, Alberti A, Maggioni F, Rossi C, Floridi A, Calabresi P (2006) Clinical-biochemical correlates of migraine attacks in rizatriptan responders and non-responders. Cephalalgia 26(3):257\u2013265. https:\/\/doi.org\/10.1111\/j.1468-2982.2005.01016.x","journal-title":"Cephalalgia"},{"issue":"1","key":"13202_CR13","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s10194-022-01502-z","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, Lampl C, Amin FM, Braschinsky M, Deligianni C, Ulud\u00fcz D, Versijpt J, Ducros A, Gil-Gouveia R, Katsarava Z, Martelletti P, Ornello R, Raffaelli B, Boucherie DM, Pozo-Rosich P, Sanchez-Del-Rio M, Sinclair A, Maassen van den Brink A, Reuter U (2022) European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure. J Headache Pain 23(1):133. https:\/\/doi.org\/10.1186\/s10194-022-01502-z","journal-title":"J Headache Pain"},{"issue":"4","key":"13202_CR14","doi-asserted-by":"publisher","first-page":"333102424124565","DOI":"10.1177\/03331024241245658","volume":"44","author":"W Rattanawong","year":"2024","unstructured":"Rattanawong W, Rapoport A, Srikiatkhachorn A (2024) Medication \u201cunderuse\u201d headache. Cephalalgia 44(4):3331024241245658. https:\/\/doi.org\/10.1177\/03331024241245658","journal-title":"Cephalalgia"},{"issue":"1","key":"13202_CR15","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s10194-022-01498-6","volume":"23","author":"P Barbanti","year":"2022","unstructured":"Barbanti P, Egeo G, Aurilia C, Altamura C, d\u2019Onofrio F, Finocchi C, Albanese M, Aguggia M, Rao R, Zucco M, Frediani F, Filippi M, Messina R, Cevoli S, Carnevale A, Fiorentini G, Messina S, Bono F, Torelli P, Proietti S, Bonassi S, Vernieri F (2022) Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients. J Headache Pain 23(1):138. https:\/\/doi.org\/10.1186\/s10194-022-01498-6","journal-title":"J Headache Pain"},{"key":"13202_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.895476","author":"M Nowaczewska","year":"2022","unstructured":"Nowaczewska M, Straburzy\u0144ski M, Waliszewska-Pros\u00f3\u0142 M, Meder G, Janiak-Kiszka J, Ka\u017amierczak W (2022) Cerebral blood flow and other predictors of responsiveness to erenumab and fremanezumab in migraine\u2014a real-life study. Front Neurol. https:\/\/doi.org\/10.3389\/fneur.2022.895476","journal-title":"Front Neurol"},{"issue":"1","key":"13202_CR17","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/ana.410330109","volume":"33","author":"PJ Goadsby","year":"1993","unstructured":"Goadsby PJ, Edvinsson L (1993) The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 33(1):48\u201356. https:\/\/doi.org\/10.1002\/ana.410330109","journal-title":"Ann Neurol"},{"issue":"12","key":"13202_CR18","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1517\/14656566.2013.806487","volume":"14","author":"MB Ram\u00edrez Rosas","year":"2013","unstructured":"Ram\u00edrez Rosas MB, Labruijere S, Villal\u00f3n CM, Maassen Vandenbrink A (2013) Activation of 5-hydroxytryptamine1B\/1D\/1F receptors as a mechanism of action of antimigraine drugs. Expert Opin Pharmacother 14(12):1599\u20131610. https:\/\/doi.org\/10.1517\/14656566.2013.806487","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"13202_CR19","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s10194-018-0927-2","volume":"19","author":"CE Christensen","year":"2018","unstructured":"Christensen CE, Younis S, Deen M, Khan S, Ghanizada H, Ashina M (2018) Migraine induction with calcitonin gene-related peptide in patients from erenumab trials. J Headache Pain 19(1):105. https:\/\/doi.org\/10.1186\/s10194-018-0927-2","journal-title":"J Headache Pain"},{"issue":"1","key":"13202_CR20","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s10194-018-0850-6","volume":"19","author":"JA Waschek","year":"2018","unstructured":"Waschek JA, Baca SM, Akerman S (2018) PACAP and migraine headache: immunomodulation of neural circuits in autonomic ganglia and brain parenchyma. J Headache Pain 19(1):23. https:\/\/doi.org\/10.1186\/s10194-018-0850-6","journal-title":"J Headache Pain"},{"issue":"9","key":"13202_CR21","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1056\/NEJMoa2314577","volume":"391","author":"M Ashina","year":"2024","unstructured":"Ashina M, Phul R, Khodaie M, L\u00f6f E, Florea I (2024) A monoclonal antibody to PACAP for migraine prevention. N Engl J Med 391(9):800\u2013809. https:\/\/doi.org\/10.1056\/NEJMoa2314577","journal-title":"N Engl J Med"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13202-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13202-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13202-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T20:32:39Z","timestamp":1757190759000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13202-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,19]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["13202"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13202-0","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,19]]},"assertion":[{"value":"27 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"C.V. received personal fees from Eli Lilly, Abbvie, and Lundbeck. F.D.C. received personal fees from TEVA, Eli Lilly, Novartis, and Abbvie. L.F.I received financial support, honoraria for scientific lectures and presentations, consulting fees for the participation in advisory boards, and support for attending meetings from: Teva, Eli Lilly, Lundbeck, Pfizer, Organon, and AbbVie; he is Associate Editor for Frontiers in Neurology Headache and Neurogenic Pain section and Review Editor for Therapeutic Advances in Neurological Disorder. Other authors have no conflicting interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study was approved as a part of the\n                      Registro Italiano Cefalee (RICe)\n                      study by the local Ethics committee (CEAVC\n                      Studio RICe, 14591_oss\n                      and subsequent amendments\n                      2022-609; 2023\n                      ).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"468"}}